New drug combo aims to outsmart resistant lung cancer
Disease control
Recruiting now
This phase 2 trial is testing whether adding savolitinib to osimertinib can help people with a certain type of advanced lung cancer (EGFR-mutated NSCLC) that has become resistant to osimertinib. The study enrolls 60 adults whose tumors have low levels of MET amplification. Partic…
Phase: PHASE2 • Sponsor: Qingdao Central Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC